Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Screening for hereditary diseases. What other screening?].

J P Farriaux1, J L Dhondt, L Moreno

  • 1Centre Régional Nord-Pas-de-Calais de Dépistage Néonatal, Faculté de Médecine de Lille.

Annales De Biologie Clinique
|January 1, 1988
PubMed
Summary

Neonatal screening for metabolic diseases is complex. Currently, only phenylketonuria and congenital hypothyroidism meet criteria for effective mass screening programs.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A novel 22bp deletion in a Tunisian phenylketonuria family.

Pathologie-biologie·2012
Same author

[Guidelines relative to the collection and handling management of biological samples].

Annales de biologie clinique·2011
Same author

[Guidelines concerning sample reception and request recording of laboratory tests].

Annales de biologie clinique·2011
Same author

[Management of pre-analytical nonconformities].

Annales de biologie clinique·2011
Same author

[Guidelines concerning stat laboratory process].

Annales de biologie clinique·2011
Same author

[Self assesment grid for pre-examination phase].

Annales de biologie clinique·2011

Area of Science:

  • Medical Genetics
  • Neonatal Medicine
  • Public Health

Context:

  • The success of neonatal screening for phenylketonuria and congenital hypothyroidism prompts consideration of other metabolic diseases.
  • Mass screening requires diseases to be treatable, not clinically obvious, requiring prompt therapy to prevent disabilities, with reasonable frequency and easy detection.

Purpose:

  • To evaluate the feasibility of expanding neonatal mass screening programs to include other metabolic diseases.
  • To discuss the suitability of congenital adrenal hyperplasia, cystic fibrosis, Duchenne muscular dystrophy, and hypercholesterolemia for neonatal screening.

Summary:

  • Congenital adrenal hyperplasia requires strategy adjustments for timely results. Cystic fibrosis screening needs assay adaptation and more data on early management efficacy.
  • Duchenne muscular dystrophy lacks treatment, offering only genetic counseling. Hypercholesterolemia requires definition of a suitable marker and treatment.
  • Pilot programs are evaluating these issues, but consensus remains that only phenylketonuria and hypothyroidism currently meet efficient mass screening criteria.

Impact:

  • Highlights the stringent criteria for effective neonatal mass screening programs.
  • Identifies challenges and knowledge gaps for expanding newborn screening beyond established conditions.
  • Reinforces the importance of treatability and early intervention in public health screening initiatives.

Related Experiment Videos